These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 25795473)

  • 1. Anakinra for the treatment of acute severe gout in critically ill patients.
    Thueringer JT; Doll NK; Gertner E
    Semin Arthritis Rheum; 2015 Aug; 45(1):81-5. PubMed ID: 25795473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of acute gouty arthritis in complex hospitalized patients with anakinra.
    Ghosh P; Cho M; Rawat G; Simkin PA; Gardner GC
    Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1381-4. PubMed ID: 23650178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of Anakinra in Acute Crystalline Diseases: A Retrospective Study Comparing a University Hospital with a Veterans Affairs Medical Center.
    Desmarais J; Chu CQ
    J Rheumatol; 2019 Jul; 46(7):748-750. PubMed ID: 30442822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of Anakinra in Hospitalized Patients with Crystal-associated Arthritis.
    Liew JW; Gardner GC
    J Rheumatol; 2019 Oct; 46(10):1345-1349. PubMed ID: 30647192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of anakinra for various types of crystal-induced arthritis in complex hospitalized patients: a case series and review of the literature.
    Aouba A; Deshayes S; Frenzel L; Decottignies A; Pressiat C; Bienvenu B; Boue F; Damaj G; Hermine O; Georgin-Lavialle S
    Mediators Inflamm; 2015; 2015():792173. PubMed ID: 25922564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of anakinra in gout patients with stage 4-5 chronic kidney disease or kidney transplantation: A multicentre, retrospective study.
    Loustau C; Rosine N; Forien M; Ottaviani S; Juge PA; Lioté F; Bardin T; Richette P; Dieudé P; Richez C; Bannwarth B; Schaeverbeke T; Ea HK; Truchetet ME
    Joint Bone Spine; 2018 Dec; 85(6):755-760. PubMed ID: 29654950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases.
    Ottaviani S; Moltó A; Ea HK; Neveu S; Gill G; Brunier L; Palazzo E; Meyer O; Richette P; Bardin T; Allanore Y; Lioté F; Dougados M; Dieudé P
    Arthritis Res Ther; 2013; 15(5):R123. PubMed ID: 24432362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot study of IL-1 inhibition by anakinra in acute gout.
    So A; De Smedt T; Revaz S; Tschopp J
    Arthritis Res Ther; 2007; 9(2):R28. PubMed ID: 17352828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic role of anakinra, an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction/macrophage activating syndrome in critically ill children*.
    Rajasekaran S; Kruse K; Kovey K; Davis AT; Hassan NE; Ndika AN; Zuiderveen S; Birmingham J
    Pediatr Crit Care Med; 2014 Jun; 15(5):401-8. PubMed ID: 24583503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-1 as a therapeutic target in gout.
    Dumusc A; So A
    Curr Opin Rheumatol; 2015 Mar; 27(2):156-63. PubMed ID: 25633244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic tophaceous gout.
    Dönmez S; Pamuk ÖN
    J Rheumatol; 2014 Mar; 41(3):554-5. PubMed ID: 24585523
    [No Abstract]   [Full Text] [Related]  

  • 12. Interleukin 1 Receptor Antagonist Anakinra, Intravenous Immunoglobulin, and Corticosteroids in the Management of Critically Ill Adult Patients With Hemophagocytic Lymphohistiocytosis.
    Wohlfarth P; Agis H; Gualdoni GA; Weber J; Staudinger T; Schellongowski P; Robak O
    J Intensive Care Med; 2019 Sep; 34(9):723-731. PubMed ID: 28631531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra.
    McGonagle D; Tan AL; Shankaranarayana S; Madden J; Emery P; McDermott MF
    Ann Rheum Dis; 2007 Dec; 66(12):1683-4. PubMed ID: 17998217
    [No Abstract]   [Full Text] [Related]  

  • 14. Anakinra in resistant gout: a case report.
    Van Wabeke J; Dhondt E; Peene I; Piette Y
    Acta Clin Belg; 2017 Aug; 72(4):293-295. PubMed ID: 27712511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-1 inhibition by anakinra in refractory chronic tophaceous gout.
    Tran AP; Edelman J
    Int J Rheum Dis; 2011 Aug; 14(3):e33-7. PubMed ID: 21816011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-1β inhibitors for the management of acute gout flares: a systematic literature review.
    Schlesinger N; Pillinger MH; Simon LS; Lipsky PE
    Arthritis Res Ther; 2023 Jul; 25(1):128. PubMed ID: 37491293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anakinra's efficacy is variable in refractory gout: report of ten cases.
    Chen K; Fields T; Mancuso CA; Bass AR; Vasanth L
    Semin Arthritis Rheum; 2010 Dec; 40(3):210-4. PubMed ID: 20494407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of patient characteristics and gout-related health-care resource utilization and costs in patients with frequent versus infrequent gouty arthritis attacks.
    Saseen JJ; Agashivala N; Allen RR; Ghushchyan V; Yadao AM; Nair KV
    Rheumatology (Oxford); 2012 Nov; 51(11):2004-12. PubMed ID: 22829689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ACTH as a treatment for acute crystal-induced arthritis: update on clinical evidence and mechanisms of action.
    Daoussis D; Antonopoulos I; Andonopoulos AP
    Semin Arthritis Rheum; 2014 Apr; 43(5):648-53. PubMed ID: 24762710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying Patient Candidates for IL-1 Inhibition: Lessons From Real-World Cases.
    Avram A; Duarte C; Santos MJ; Papagoras C; Ritis K; Scarpioni R; Schmidt WA; Skendros P
    Joint Bone Spine; 2015 Oct; 82 Suppl 1():eS17-29. PubMed ID: 26717798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.